Stem Cell Research (May 2022)
Generation of induced pluripotent stem cell line derived from FNAIT patient with CD36 deficiency mutations
Abstract
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) caused by anti-CD36 isoantibodies is a common disease and the frequency of type I CD36 deficiency is relatively high in eastern Asian populations. Currently, patient-specific induced pluripotent stem cells (hiPSC) are believed to be useful tools for studying anti-CD36 mediated FNAIT and finding new therapeutic approaches to the disease. We generated an iPSC line from peripheral blood mononuclear cells of a patient carrying a 329-330delAC of the CD36 gene. The iPSC expressed pluripotency markers, gave rise to derivatives of three germ layers during spontaneous differentiation, had a normal karyotype, and retained the patient-specific mutation.